RayKnowChina Research Map
Shortlist

RecruitingBreast cancerPhase 3

Registered title, quoted from ClinicalTrials.gov

YL202 Versus Treatment of Physician's Choice in Patients With HR+/HER2- Breast Cancer

An open trial on breast cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Study siteFudan University Shanghai Cancer Center复旦大学附属肿瘤医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07461454, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 5

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (5 points)Hide the checklist
  1. 18 years to 75 years; sex: women only

    Registered eligibility fields

  2. Histologically and/or cytologically confirmed locally advanced or metastatic HR+/HER2- breast cancer who are not candidates for curative surgery or radiotherapy.

    Inclusion criterion 2

  3. Female patients of childbearing potential must agree to use highly effective contraception from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.

    Inclusion criterion 8

    Have prior treatment with an agent targeting HER3.

    Exclusion criterion 1

    Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.

    Exclusion criterion 4

  4. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.

    Inclusion criterion 6

  5. Have at least 1 extracranial measurable lesion as a target lesion per RECIST 1.1.

    Inclusion criterion 4

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; blood tests: counts, liver and kidney function; other conditions the trial excludes; pregnancy, breastfeeding and contraception.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07461454, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Have been informed of the study before the start of the study and voluntarily sign name and date on the informed consent form.
  • Histologically and/or cytologically confirmed locally advanced or metastatic HR+/HER2- breast cancer who are not candidates for curative surgery or radiotherapy.
  • Patients who had failed at least one line of systemic chemotherapy in unresectable locally advanced, recurrent, or metastatic stage.
  • Have at least 1 extracranial measurable lesion as a target lesion per RECIST 1.1.
  • Tumor tissue samples can be provided at the time of diagnosis of locally advanced or metastatic tumors.
  • Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.
  • Have Adequate organ and bone marrow function within 7 days prior to the first dose.
  • Female patients of childbearing potential must agree to use highly effective contraception from screening throughout the duration of the study and for at least 6 months after the last dose of study drug.
  • Have a expected survival ≥ 3 months.
  • Have ability and willingness to comply with protocol-specified visits and procedures.

Exclusion Criteria:

  • Have prior treatment with an agent targeting HER3.
  • Have prior treatment with topoisomerase I inhibitor or an ADC that consists of topoisomerase I inhibitor.
  • Have insufficient washout period for prior anticancer therapy prior to first dose of the study drug.
  • Have major surgery (excluding diagnostic surgery) within 4 weeks prior to the first dose of study drug or anticipation of major surgery during the study.
  • Leptomeningeal metastases or carcinomatous meningitis, spinal cord compression.
  • Have uncontrolled or clinically significant cardiovascular and cerebrovascular disease.
  • Have clinically significant concomitant pulmonary diseases.
  • Have uncontrolled pleural effusion, abdominal effusion.
  • Have serious infection within 4 weeks prior to the first dose.
  • Have a history of severe hypersensitivity reactions to the drug substance, inactive ingredients in the drug product, or other monoclonal antibodies.

Quoted from ClinicalTrials.gov, NCT07461454, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07461454, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07461454